Cancer Commons founder Marty Tenenbaum, PhD, will deliver a Keynote Chat at Cancer Advance Boston on Wednesday, April 24 at 2:40pm. This annual gathering is “an invitation-only, off-the-record forum that brings together the past, present and future leaders to network and share expertise in cancer therapeutics.”
Marty, who founded Cancer Commons after dealing with his own cancer diagnosis, will discuss some of the major problems he’s working to fix: “Clinical oncology is in crisis. Patients and physicians are overwhelmed by a tsunami of research findings, conflicting expert opinions, and a shortage of actionable data. Meanwhile trials cost too much, take too long, and are too narrowly focused. Individual outcomes vary widely and too many trials compete for too few patients. Learn how AI can help bio-pharma slash the time and cost of developing drugs, physicians make better decisions, and patients achieve superior outcomes.”
Click here to learn more about Cancer Advance Boston.
We warmly invite everyone in the Cancer Commons community to an afternoon of lovely and lively music on Sunday June 9, in Los Altos, CA. Organized by our very own Masako Yokota, a cancer survivor and classically trained vocalist, the concert will feature a selection of tunes by renowned American composer George Gershwin. Ms. Yokota will be joined by local pianist and accompanist David Stein; together, they will perform a delightful program of Gershwin’s classical compositions and American songs.
All proceeds from the concert will go to Cancer Commons, which aims to connect patients and their physicians with the knowledge they need to achieve the best possible outcomes, help them access relevant treatments and trials, and continuously learn from their experiences. We hope you will join us for a wonderful afternoon of music while supporting this important cause!
When: Sunday, June 9, 3:30 to 5:00 pm Where: Bridges Community Church, 625 Magdalena Ave, Los Altos, CA 94024 Suggested donation: $20 More info:firstname.lastname@example.org
Gershwin photo (left) from George Grantham Bain collection, Library of Congress
LOS ALTOS, Calif., March 12, 2019 /PRNewswire/ — xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201. Part of this Expanded Access program is an intermediate size Expanded Access protocol for ONC201 in patients with H3 K27M-mutant glioma entitled “ONC018: Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas” that was recently accepted by the U.S. Food and Drug Administration (FDA).
The H3 K27M mutation has been identified as an important prognostic indicator in aggressive midline gliomas that involve specific parts of the brain, including the thalamus, pons, or spinal cord. In 2016, the World Health Organization categorized any midline brain tumor that contains the H3 K27M mutation as the highest grade (IV) because the mutation confers such a poor prognosis. Beyond palliative radiation, no medical therapy has been shown to provide clinical benefit for patients with this mutation in their tumor. Pediatric patients are particularly impacted by this mutation, especially those with DIPG where 70-80% of the patients have the mutation. Continue reading…
Treatment for metastatic pancreatic cancer has seen progress in recent years, but outcomes remain poor and treatment advances that can prolong patients’ lives, even for a few months, are eagerly awaited. Two papers published today in the scientific journal Nature Medicine report that a new combination of two drugs that are FDA-approved for other conditions may significantly delay progression of pancreatic cancer in cells and in mice. Furthermore, the first patient treated with this combination experienced a prolonged response that lasted almost 6 months.
In light of these promising results, Cancer Commons is partnering with xCures to track the experiences of patients who choose to try this new combination therapy. Continue reading…
“Big data and machine learning have the potential to improve health, detecting disease at an earlier stage and personalizing interventions. The key ingredient, some say, is applying algorithms to population-wide datasets. But the question remains: is it enough to train smarter algorithms with broader datasets? What other approaches, diagnostics tools, and technologies do we need to accurately assess a patient’s unique needs and build a personalized intervention? A panel of experts across diagnostics, informatics, and therapeutics from government, academia, integrated health centers, data science, and biopharma will lead a highly interactive exploration of these issues and predict what it will take to realize the role of data science enabling personalized medicine.”
Cancer Commons founder Marty Tenenbaum, PhD, will speak at the upcoming Bridging Clinical Research & Clinical Health Care Collaborative at the National Academy of Sciences in Washington, DC, on March 4 at 5:00 pm. Marty, who founded Cancer Commons after his own battle with melanoma, will facilitate an expert panel discussion on “Reinventing Clinical Research and Cancer Care.” That same day, he will also lead a lunchtime discussion on “Shifting the Clinical Trials Paradigm From Approving Drugs to Curing Patients.”
In preparation for the conference, Marty has written a piece for Bridging Clinical that outlines his take on the increasing demand for patients in clinical research. An excerpt: “Those familiar with the current drug development process express skepticism that the system can ever be changed — and for good reason; many have tried and failed. However, a confluence of trends, from patient activism to the explosion of new therapies to an unprecedented open regulatory environment, make a paradigm shift from drug-developer-centric to patient-centric trials both necessary and possible.” Click here to read the full article.
In September, we announced our collaboration with Musella Foundation, xCures, and Oncoceutics to help patients access ONC201, a potential new treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3 K27M.
Since then, several news stories have reported promising developments for ONC201. Check out the coverage:
Atrium Health: “Finding hope in the face of brain cancer: After being diagnosed with a brain tumor, Amanda’s future was uncertain. But participating in a Phase 2 clinical trial has given her more time, more hope and a new mission.” (Also covered on WSOC-TV)
Chief scientist Emma Shtivelman’s expert, science-based opinion made such logical sense, and it also felt right in my soul. —Ellen McGregor Kortan
I always say that Emma was an angel that appeared in my life. Rapidly, I saw that her advice was professional and that her insights matched the latest publications, so I have developed very strong trust in her… Moreover, what I appreciate the most about Emma is her human goodness and empathy. I have never felt I was just a case for her. She is really dedicated to the patient. — Marilou Gougeon
Emma is really up and up on the latest and newest available treatments… On top of that, you can tell that she truly cares…There is no money in the world that can buy that sort of support. It is the ultimate second opinion. — Phil Kauffman
To many of the patients whom she personally helps to make treatment decisions in the fight of their lives, chief scientist Emma Shtivelman, PhD, represents the heart, soul, and brain of Cancer Commons.Continue reading…